Why Did AngioDynamics Stock Pop Today?

Key Points

• AngioDynamics beat earnings this morning.

• The company did that not by earning more than expected, though, but by losing less than expected.

• Full-year earnings will still be negative.

• 10 stocks we like better than AngioDynamics ›

AngioDynamics (NASDAQ: ANGO) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning.

Heading into the report, analysts forecast AngioDynamics would lose $0.12 per share in its fiscal Q1 2026, on sales of $72.7 million. In fact, the medical devices maker lost only $0.10 per share (technically a "beat," but still a loss), and sales were 75.7 million.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »

Image source: Getty Images.

AngioDynamics Q1 earnings

CEO Jim Clemmer declared: "We had an outstanding first quarter as we continued to build off of the strong momentum created in fiscal 2025."

But not all of AngioDynamics's news was good. Sales grew 12% year over year, propelled by 26% growth in its med tech segment, but only 2% growth in medical devices. Despite earning 55.3% gross profit margins on these sales, though -- 90 basis points better than one year ago -- actual earnings as calculated according to generally accepted accounting principles (GAAP) were considerably worse than the $0.10 per-share "adjusted" profit noted above.

Two-and-a-half times worse, in fact. GAAP losses for the quarter came to $0.26 per share.

Is AngioDynamics stock a buy?

Turning to guidance, AngioDynamics told investors to expect higher sales this fiscal year, $308 million to $313 million, with med tech sales growing to the mid-teens and offsetting flat performance at the medical devices business.

Management didn't give guidance for GAAP earnings, but admitted adjusted profits will run negative all year long -- $0.23 to $0.33 per share. And while free cash flow will be "positive," AngioDynamics wasn't able to say by how much.

Long story short, nearly four decades after its founding, AngioDynamics remains years away from profitability. Any investors losing patience would be best advised to use today's stock price surge as an opportunity to sell, and exit the stock.

Should you invest $1,000 in AngioDynamics right now?

Before you buy stock in AngioDynamics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AngioDynamics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $631,456!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,147,755!*

Now, it’s worth noting Stock Advisor’s total average return is 1,064% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of September 29, 2025

Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.